Vident Advisory, LLC Myriad Genetics Inc Transaction History

Vident Advisory, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$17.98 - $25.47 $28,821 - $40,828	-1,603 Reduced 12.87%	10,848 $265 Million
Q1 2024 May 14, 2024	SELL	$17.59 - $23.59 $6,174 - $8,280	-351 Reduced 2.74%	12,451 $265 Million
Q4 2023 Feb 14, 2024	BUY	$13.91 - $21.32 $10,029 - $15,371	721 Added 5.97%	12,802 $245 Million
Q3 2023 Feb 21, 2024	SELL	$15.99 - $23.22 $11,528 - $16,741	-721 Reduced 5.63%	12,081 $194 Million
Q3 2023 Nov 14, 2023	BUY	$15.99 - $23.22 $193,175 - $280,520	12,081 New	12,081 $194 Million

253

90.5M

100K

34K

Ticker MYGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 80,634,800
Market Cap $1.08B
Description
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...

Get notified when there are updates to the investment portfolio of Vident Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Advisory, LLC with notifications on news.